Bio-equivalence of IR Tablet against ER Tablet [Design Issues]

posted by Jasim Uddin – Bangladesh, 2018-06-20 13:29 (1509 d 14:26 ago) – Posting: # 18929
Views: 2,204

Dear Sirs

Does anyone know about BE Study design of Immediate Release Formulation against Extended Release Formulation?

We manufacture Potassium Chloride 600 mg IR tablet. But no RLD is available as IR tablet. RLD SLOW-K 600 mg of Novartis is available as ER tablet.

Is it possible to design BE study of our IR formulation of Potassium Chloride 600 mg against SLOW-K 600 mg ER tablet?

Would appreciate kind advice of the experts in this forum.

Kind regards

Jasim


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,288 posts in 4,665 threads, 1,583 registered users;
online 4 (0 registered, 4 guests [including 3 identified bots]).
Forum time: Monday 03:55 CEST (Europe/Vienna)

Don’t compromise yourself.
You are all you’ve got.    Janis Joplin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5